In the US, psychedelics like psilocybin and MDMA sit in Schedule I — the government's most restricted drug category, meaning they're treated as having no accepted medical use and high abuse potential. The DEA (the agency that enforces drug laws) almost always waits for the FDA to approve a drug before loosening those restrictions. Since no FDA approval is coming in 2026, the scheduling won't change either.
Three agents (DEA, legislator, FDA reviewer) concur that agencies and Congress sequence rescheduling after FDA action, not before. DEA historically follows FDA/HHS scheduling recommendations. The lone dissent (MAPS researcher) reflects advocacy optimism rather than procedural reality.